Riskpilot← Back to searchSign inGet full accessVleraLab AB
ABActiveOrg 5592242183Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20190 employees
Revenue 2024
SEK 0
EBITDA margin
—
Equity ratio
-290.0%
Financial strength
Net profit 2024
SEK -15K
-67% vs 2023
| Revenue | SEK 0 | — |
| EBITDA | SEK -6K | — |
| Net profit | SEK -15K | -67% |
| Total assets | SEK 10K | -52% |
| Equity | SEK -29K | -107% |
| Employees | 0 | — |
Legal name
VleraLab AB
Org number
5592242183
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
28 oktober 2019
Share capital
SEK 50 000
Employees
0
VAT registered
Yes
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Bolaget skall bedriva import och försäljning av laboratorieutrustning med tillhörande service, samt idka därmed förenlig verksamhet.
Address
Email
sh.limoni@outlook.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 266 | — | 0 | 0 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | −37 | 0 | — | — | −6 |
| Depreciation & amort. | −0 | — | −9 | −9 | −9 |
| EBIT | −37 | 0 | −9 | −9 | −15 |
| Net financials | — | — | — | — | — |
| Profit before tax | −37 | 0 | −9 | −9 | −15 |
| Tax | −0 | — | −0 | −0 | −0 |
| Net profit | −37 | — | −9 | −9 | −15 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 61 | — | 27 | 21 | 10 |
| Equity | 13 | — | −5 | −14 | −29 |
| Long-term debt | 0 | — | 0 | 0 | 0 |
| Short-term debt | 48 | — | 32 | 35 | 40 |
| Total debt | 48 | — | 32 | 35 | 40 |
EBITDA margin
-600000.0%
This company
15.8%
Market median
-3797568% vs market
20202024
Equity ratio
-290.0%
This company
38.2%
Market median
-859% vs market
20202024
Return on equity
-1500000.0%
This company
18.4%
Market median
-8152274% vs market
20202024
Net profit margin
-1500000.0%
This company
8.1%
Market median
-18518619% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
1.34×
This company
0.62×
Market median
-116% vs market
20202024
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2019-10-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
SL Chief Executive Officer | Chief Executive Officer | 2026 |
| Former (1) | ||
AL Chief Executive Officer | Chief Executive Officer | 2020 – 2026 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Deputy Board Member | 2022 | |
| Deputy Board Member | 2022 | |
| Former (2) | ||
| Deputy Board Member | 2020 – 2022 | |
| Deputy Board Member | 2020 – 2020 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of VleraLab AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Ardjen Limoni | Chief Executive Officer | 0 companies |
| Shuhrete Limoni | Chief Executive Officer | 0 companies |
| Zymri Limoni | Deputy Board Member | 0 companies |
| Shpetim Prekaj | Deputy Board Member | 0 companies |
| Zymri Limoni | Deputy Board Member | 0 companies |
| Ardit Çela | Deputy Board Member | 0 companies |